FineMark National Bank & Trust’s Oramed Pharmaceuticals ORMP Stock Holding History

FineMark National Bank & Trust’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,473	Closed	-$21K	–	803
2016 Q4	$21K	Hold	3,473	–	–	﹤0.01%	817
2016 Q3	$25K	Hold	3,473	–	–	﹤0.01%	766
2016 Q2	$29K	Hold	3,473	–	–	﹤0.01%	745
2016 Q1	$23K	Hold	3,473	–	–	﹤0.01%	760
2015 Q4	$30K	Hold	3,473	–	–	﹤0.01%	730
2015 Q3	$19K	Hold	3,473	–	–	﹤0.01%	859
2015 Q2	$20K	Hold	3,473	–	–	﹤0.01%	892
2015 Q1	$22K	Hold	3,473	–	–	﹤0.01%	863
2014 Q4	$16K	Hold	3,473	–	–	﹤0.01%	947
2014 Q3	$28K	Hold	3,473	–	–	﹤0.01%	794
2014 Q2	$33K	Hold	3,473	–	–	0.01%	750
2014 Q1	$41K	Hold	3,473	–	–	0.01%	668
2013 Q4	$54K	Hold	3,473	–	–	0.01%	559
2013 Q3	$22K	Hold	3,473	–	–	0.01%	775
2013 Q2	$28K	Buy	+3,473	New	+$28.6K	0.01%	693

Other funds holding ORMP

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

FineMark National Bank & Trust's ORMP Position: Q1 2017 in Review

FineMark National Bank & Trust sold out of Oramed Pharmaceuticals (ORMP) in Q1 2017, closing a stake of 3,473 shares — an estimated $21K sold.

FineMark National Bank & Trust first reported a position in ORMP in Q2 2013 and held it in 15 quarters. The position peaked at $54K in Q4 2013. 21 funds tracked by Wall St. Rank hold ORMP as of Q1 2017.

FineMark National Bank & Trust reported no remaining Oramed Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
FineMark National Bank & Trust sold 3,473 Oramed Pharmaceuticals shares in Q1 2017, an estimated $21K.
FineMark National Bank & Trust first reported a position in Oramed Pharmaceuticals in Q2 2013 and held it in 15 quarters.
FineMark National Bank & Trust's Oramed Pharmaceuticals position peaked at $54K in Q4 2013.
21 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2017.

Based on FineMark National Bank & Trust's 13F filing for Q1 2017, filed 12 May 2017.